Indication
Virus Diseases
21 clinical trials
38 products
3 drugs
Product
RG SAM (CNE) vaccineProduct
RG SAMClinical trial
Safety and Immunogenicity of GSK's Rabies G SAM (CNE) Vaccine [GSK3903133A] in Healthy Adults.Status: Completed, Estimated PCD: 2021-07-28
Product
SalineProduct
RabAvertClinical trial
A Randomized, Double-blind, Open for Active Comparator, Parallel-group, Multicenter Phase 2b Study to Assess the Efficacy and Safety of Three Different Doses of P2X3 Antagonist (BAY1817080) Versus Placebo and Elagolix 150 mg in Women With Symptomatic EndometriosisStatus: Terminated, Estimated PCD: 2022-01-17
Product
EncepurProduct
CoV2 SAMClinical trial
A Phase I, First-Time-in Human (FTiH), Open-label, Dose Escalation, Non-randomized Study to Assess Safety, Reactogenicity and Immune Response of a CoV-2 SAM (LNP) Vaccine When Administered Intramuscularly on a 0, 1 Month Schedule in Healthy Adults 18 to 50 Years of AgeStatus: Completed, Estimated PCD: 2021-06-04
Product
Encepur AdultsProduct
VapendavirClinical trial
A Trial in Participants With Chronic Obstructive Pulmonary Disease (COPD) to Evaluate the Impact of Vapendavir on the Development of Lower Respiratory Tract Symptoms Following Rhinovirus ChallengeStatus: Recruiting, Estimated PCD: 2024-12-30
Product
PlaceboProduct
RG SAM (CNE)Product
Saline PlaceboProduct
aH5N8cProduct
aH5N6cClinical trial
A Phase 2, Multi-Center, Randomized, Observer-Blind Study, to Evaluate Safety and Immunogenicity of Homologous or Heterologous Priming and Booster Vaccinations With H5N8 or H5N6 MF59-adjuvanted, Cell Culture-derived Influenza Vaccine in Healthy Subjects ≥18 Years of AgeStatus: Active (not recruiting), Estimated PCD: 2024-04-25
Product
RG SAM vaccineClinical trial
A Phase III Randomized Blinded Study to Evaluate SYN023 Compared to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies in Adults With Category III Rabies Exposure RisksStatus: Completed, Estimated PCD: 2022-06-24
Clinical trial
A Randomized, Observer-blind, Active Comparator-controlled, Multicenter, Phase 3 Study to Assess the Efficacy, Safety, and Immunogenicity of a Plant-derived Quadrivalent VLP Influenza Vaccine in Adults 65 Years of Age and OlderStatus: Completed, Estimated PCD: 2019-05-17
Product
Quadrivalent VLP VaccineProduct
Fluarix QuadrivalentClinical trial
A Single Arm, Open Label, Single Dose and Multiple Dose Study to Evaluate Pharmacokinetics, Safety & Tolerability of 101-PGC-005 in Healthy, Adult, Human SubjectsStatus: Active (not recruiting), Estimated PCD: 2022-11-03
Clinical trial
A Randomized, Observer-blind, Multicenter, Phase 3 Study to Evaluate the Lot Consistency, Immunogenicity, and Safety of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Healthy Adults 18-49 Years of AgeStatus: Completed, Estimated PCD: 2017-12-01
Product
SYN023Product
Human Rabies Immune GlobulinProduct
Rabies VaccineProduct
101-PGC-005Product
A/H2N3c + MF59Clinical trial
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59-adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or UnprimedStatus: Completed, Estimated PCD: 2022-10-24
Product
A/H2N3cClinical trial
A Phase 1, Randomized, Observer-Blind, Multi-Center, Dose Ranging Study to Evaluate the Immunogenicity, Safety and Tolerability of Different Formulations of an Adjuvanted or Non-Adjuvanted Cell Culture-derived A/H2N3 Subunit Influenza Virus Vaccine in Healthy Subjects 18 Years and AboveStatus: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
A Randomized, Observer-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Adults 18-64 Years of AgeStatus: Completed, Estimated PCD: 2018-05-02
Product
AlloStimClinical trial
Safety and Efficacy of ALLOSTIM® Universal Anti-Viral Immunodulatory Vaccine for Healthy Elderly AdultsStatus: Completed, Estimated PCD: 2023-03-01
Clinical trial
A Phase II Study of Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)Status: Recruiting, Estimated PCD: 2025-11-24
Drug
AtezolizumabClinical trial
Evaluating the Durability of the Human Immune Response to the JYNNEOS Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) VaccineStatus: Not yet recruiting, Estimated PCD: 2025-12-01
Product
JYNNEOSClinical trial
Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19Status: Completed, Estimated PCD: 2021-06-01
Drug
TocilizumabProduct
DexamethasoneClinical trial
VRC 705: A Phase 2/2B, Randomized Trial to Evaluate the Safety, Immunogenicity and Efficacy of a Zika Virus DNA Vaccine in Healthy Adults and AdolescentsStatus: Completed, Estimated PCD: 2019-10-04
Product
VRC-ZKADNA090-00-VPClinical trial
A Phase 2, Open-label, Study to Evaluate the Safety and Immunogenicity of a Heterologous 2-dose Vaccination Regimen Using Ad26.ZEBOV, MVA-BN-Filo in Adults and Children Originally Enrolled in the Control Arm of the EBOVAC-Salone StudyStatus: Active (not recruiting), Estimated PCD: 2023-12-31
Product
Ad26.ZEBOV, MVA-BN-FiloClinical trial
A Multicenter Controlled Open-label Trial of Evaluating Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate and Entecavir in Acute-on-chronic Liver Failure of Chronic Hepatitis B PatientsStatus: Recruiting, Estimated PCD: 2021-04-30
Product
Tenofovir AlafenamideDrug
AN0025Clinical trial
Proof-of-concept Trial to Evaluate the Safety and Efficacy of Maraviroc in Severe Acute Respiratory Syndrome (SARS) Coronavirus-2 (CoV-2) Infected Patients Hospitalized for COVID-19Status: Completed, Estimated PCD: 2021-07-08
Product
MaravirocClinical trial
A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-3682B (MK-5172 + MK-3682 + MK-8408 Fixed Dose Combination (FDC)) in Subjects With Chronic HCV GT1 or GT3 Infection Who Have Failed a Direct Acting Antiviral RegimenStatus: Terminated, Estimated PCD: 2017-01-09
Product
MK-3682BProduct
Ribavirin